JP2016527307A - 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物 - Google Patents

胆汁酸−脂肪酸抱合体を含む抗座瘡組成物 Download PDF

Info

Publication number
JP2016527307A
JP2016527307A JP2016532792A JP2016532792A JP2016527307A JP 2016527307 A JP2016527307 A JP 2016527307A JP 2016532792 A JP2016532792 A JP 2016532792A JP 2016532792 A JP2016532792 A JP 2016532792A JP 2016527307 A JP2016527307 A JP 2016527307A
Authority
JP
Japan
Prior art keywords
acid
composition
fabac
acne
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016532792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527307A5 (enExample
Inventor
ダヤン，ナバ
バハラフ，アレン
Original Assignee
ガルデルム セラピューティクス リミテッド
ガルデルム セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガルデルム セラピューティクス リミテッド, ガルデルム セラピューティクス リミテッド filed Critical ガルデルム セラピューティクス リミテッド
Publication of JP2016527307A publication Critical patent/JP2016527307A/ja
Publication of JP2016527307A5 publication Critical patent/JP2016527307A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
JP2016532792A 2013-08-08 2014-08-07 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物 Pending JP2016527307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863454P 2013-08-08 2013-08-08
US61/863,454 2013-08-08
PCT/IL2014/050718 WO2015019359A1 (en) 2013-08-08 2014-08-07 Anti-acne compositions comprising bile acid-fatty acid conjugates

Publications (2)

Publication Number Publication Date
JP2016527307A true JP2016527307A (ja) 2016-09-08
JP2016527307A5 JP2016527307A5 (enExample) 2017-09-14

Family

ID=52460753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532792A Pending JP2016527307A (ja) 2013-08-08 2014-08-07 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物

Country Status (7)

Country Link
US (1) US20160175324A1 (enExample)
EP (1) EP3030229B1 (enExample)
JP (1) JP2016527307A (enExample)
CN (1) CN105611919A (enExample)
AU (1) AU2014304079A1 (enExample)
CA (1) CA2920457A1 (enExample)
WO (1) WO2015019359A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019044852A1 (ja) * 2017-08-31 2020-10-29 株式会社 資生堂 レチノイドの副作用に対する感受性の決定方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
WO2016199137A1 (en) 2015-06-10 2016-12-15 Galmed Research And Development Ltd. Low dose compositions of aramchol salts
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
US10016456B2 (en) * 2014-07-18 2018-07-10 Dabney Patents, L.L.C. Methods for treating acne vulgaris
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
KR20180036580A (ko) 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
WO2018062922A1 (ko) * 2016-09-30 2018-04-05 주식회사 유스바이오팜 수가용화된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN109503693B (zh) * 2018-12-12 2021-04-06 合肥工业大学 一种利用胆酸为原料合成Aramchol的工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535756A (ja) * 2007-08-08 2010-11-25 グレースウェイ ファーマシューティカルズ，エルエルシー フェノキシ−ピロリジン誘導体ならびにその使用および組成物
JP2011513296A (ja) * 2008-02-25 2011-04-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および皮膚の処置における治療剤としてのその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860712A (en) * 1973-04-16 1975-01-14 Sterling Drug Inc Composition and method for treatment of acne or seborrhea
IT8167097A0 (it) * 1981-01-26 1981-01-26 Unilever Nv Composizione cosmetica per il trattamento della pelle o dei capelli
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
ES2296463B1 (es) * 2005-07-13 2009-02-16 Universidade De Santiago Compostela Nuevos amidoderivados de acidos billares funcionalizados en la posicion 3 del anillo a. procedimientos para su obtencion y aplicaciones.
WO2009060452A2 (en) * 2007-11-08 2009-05-14 Galmed International Ltd. Methods and compositions for treating biliary cholesterol crystallization and related conditions
FR2940281B1 (fr) * 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique Ester de diol et d'acide gras polyinsature comme agent anti-acne
US8937194B2 (en) * 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
WO2010086864A1 (en) * 2009-02-02 2010-08-05 Galmed International Ltd. Methods and compositions for treating alzheimer's disease
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535756A (ja) * 2007-08-08 2010-11-25 グレースウェイ ファーマシューティカルズ，エルエルシー フェノキシ−ピロリジン誘導体ならびにその使用および組成物
JP2011513296A (ja) * 2008-02-25 2011-04-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および皮膚の処置における治療剤としてのその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＡＲＣＨＩＶＥＳ ＯＦ ＭＥＤＩＣＡＬ ＲＥＳＥＡＲＣＨ, vol. Vol.41, Issue 6, JPN6018015557, 2010, pages 397 - 404, ISSN: 0003787983 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019044852A1 (ja) * 2017-08-31 2020-10-29 株式会社 資生堂 レチノイドの副作用に対する感受性の決定方法
JP7267198B2 (ja) 2017-08-31 2023-05-01 株式会社 資生堂 レチノイドの副作用に対する感受性の決定方法

Also Published As

Publication number Publication date
CN105611919A (zh) 2016-05-25
EP3030229A1 (en) 2016-06-15
AU2014304079A1 (en) 2016-02-25
US20160175324A1 (en) 2016-06-23
CA2920457A1 (en) 2015-02-12
WO2015019359A1 (en) 2015-02-12
EP3030229B1 (en) 2019-03-13
EP3030229A4 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
JP2016527307A (ja) 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物
US8679552B2 (en) Acne vulgaris treatment regimen
US9056086B2 (en) Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETrE and methods of use thereof
US20150094370A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
US20070105954A1 (en) Formulation containing a carboxylic acid or an ester thereof
KR101018352B1 (ko) 봉독을 유효성분으로 하는 여드름 예방 및 치료용 조성물
JP5774004B2 (ja) ヘキサミジン類とレチノイド類を含有するニキビ改善又は治療組成物
WO1999059580A1 (en) Preventives/remedies for skin diseases
CN105611910A (zh) 包含胆汁酸-脂肪酸缀合物的抗老化组合物
JP2013500984A (ja) ダプソンとアダパレンの組み合わせ
CN102038672B (zh) 一种用于治疗痤疮的药物组合物
CA2798121C (en) Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies
JP2024516652A (ja) 過酸化ベンゾイルおよびアゼライン酸を含む外用剤およびその使用
HK1224943A1 (en) Anti-acne compositions comprising bile acid-fatty acid conjugates

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190730